Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.84 USD | +1.66% | +1.66% | +44.88% |
21/05 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
16/05 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.88% | 1.32Cr | |
+43.36% | 5.46TCr | |
-5.31% | 3.99TCr | |
+37.52% | 3.88TCr | |
+14.75% | 2.69TCr | |
-12.56% | 2.62TCr | |
-22.45% | 1.88TCr | |
+0.04% | 1.22TCr | |
+25.12% | 1.22TCr | |
+26.04% | 1.19TCr |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics to Implement 1-for-6 Reverse Stock Split